The Week Ahead: Johnson & Johnson, Abbott Laboratories Start Earnings Season
We're also watching for reports from JPMorgan, Bank of America, and other big financial-services names.
Big Pharma and Big Biotech are industries that have managed to remain healthy as the coronavirus has devastated the world and economy. Johnson & Johnson, a reigning front-runner across the major healthcare industries, holds leadership roles in diverse healthcare segments. We expect the high need for drugs should support continued demand and supply to shield this wide-moat firm, along with other big drug firms, from the impacts of the coronavirus. With only minor disruptions anticipated, the moat ratings for this industry are not expected to change.
Carole Hodorowicz does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.